The number of genes known to be involved in hereditary cancer syndromes and risk is steadily increasing. Genetic testing is recommended for the proper treatment of many cancers.

  • The information provided by hereditary genetic testing determines risk of cancer, and guides therapy.
  • Protean offers the most extensive testing panel available to ensure that genes are not missed.
  • We produce a simplified analysis report with guidance for the busy practitioner.
  • If needed, we can arrange for genetic counseling and informed consent for testing.
  • The data is protected for future use if new genes are identified.
 
shutterstock_1090856084.jpg
 
 
 
 
Screen Shot 2023-03-15 at 3.18.15 PM.png
 

Choice of Test

The practitioner can select a focused gene panel for a particular disease site, limiting the number of genes analyzed. Protean also offers a comprehensive panel that includes all of the currently known genes associated with hereditary cancer risk.

 
 
  • ABRAXAS1, AKT1, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CHEK2, DICER1, EPCAM, FANCC, FANCM, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PIK3CA, PMS2, POLD1, PTEN, RAD50, RAD51C, RAD51D, RECQL4, RINT1, SDHB, SDHD, STK11, TP53, XRCC2

  • APC, ATM, AXIN2, BLM, BMPR1A, BUB1B, CDH1, CEP57, CHEK2, EPCAM, FLCN, GALNT12, GREM1, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, RPS20, SMAD4, STK11, TP53

  • APC, ATM, AXIN2, BLM, BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, CHEK2, CTNNA1, EPCAM, KIT, MEN1, MLH1, MSH2, MSH6, MUTYH, NF1, PALB2, PDGFRA, PMS2, POLD1, POLE, PTEN, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53

  • APC, ATM, BMPR1A, BRCA1, BRCA2, CDK4, CDKN2A, EPCAM, FANCC, MEN1, MLH1, MSH2, MSH6, NF1, PALB2, PALLD, PMS2, SMAD4, STK11, TP53, TSC1, TSC2, VHL

  • APC, ATM, BMPR1A, BRCA1, BRCA2, CDK4, CDKN2A, EPCAM, FANCC, MEN1, MLH1, MSH2, MSH6, NF1, PALB2, PALLD, PMS2, SMAD4, STK11, TP53, TSC1, TSC2, VHL

  • ABRAXAS1, AKT1, ALK, ATM, AXIN2, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKN2A, CEP57, CHEK2, CTNNA1, DICER1, EPCAM, FANCC, FANCM, FLCN, GALNT12, GREM1, KIT, MEN1, MRE11, MSH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PALLD, PIK3CA, PDGFRA, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, RECQL4, RINT1, RPS20, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL, XRCC2

  • ABRAXAS1, ACTA2, ACTC1, AKT1, ALK, APC, APOB, ATM, ATP7B, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CACNA1S, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEP57, CHEK2, COL3A1, CTNNA1, DICER1, DSC2, DSG2, DSP, EGFR, EPCAM, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FBN1, FH, FLCN, GALNT12, GLA, GPC3, GREM1, HOXB13, KCNH2, KCNQ1, KIT, LDLR, LMNA, MAX, MEN1, MET, MITF, MLH1, MRE11, MSH2, MSH3, MSH6, MUTYH, MYBPC3, MYH7, MYH11, MYL2, MYL3, NBN, NF1, NF2, NTHL1, NTRK1, OTC, PALB2, PALLD, PCSK9, PDGFRA, PDGFRB, PHOX2B, PIK3CA, PKP2, PMS2, POLD1, POLE, PRKAG2, PRKAR1A, PRSS1, PTCH2, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RINT1, RPS20, RYR1, RYR2, SCN5A, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD3, SMAD4, SMARCB1, SMARCE1, SPINK1, SPRED1, STK11, SUFU, TERT, TGFBR1, TGFBR2, TMEM43, TMEM127, TNNI3, TNNT2, TP53, TPM1, TSC1, TSC2, VHL, WRN, WT1, XRCC2

  • Evaluates inherited medical syndromes & polygenetic risk scores.

  • Evaluates drug sensitivities and toxicities.

 
 
Screen Shot 2021-09-03 at 1.51.10 PM.png
 
 

How is the Test Done?

  • The test is performed on a cheek swab sample.

  • Samples can be collected in the doctor’s office or at the patient’s home.

  • DNA samples take 2-3 weeks to be sequenced and analyzed.

  • Informed consent should be completed prior to sample collection, and when the results are delivered.

 
  • It is standard practice for a genetic counselor to meet with the patient before submitting the sample, and to discuss results after the test is completed.

  • For some patients with unusual medical conditions, we can perform a broader bioinformatics analysis to search for mutations in non-cancer related genes associated with both known and unknown inherited medical conditions.

  • Protean will retain the sequencing data for the patient and practitioner to revisit in the future. The data is complex and available in formats that can be re-analyzed with various bioinformatics systems and pipelines.

 
 

Contact us now to order or receive more information.

Screen+Shot+2023-02-17+at+3.51.43+PM.jpg

 Have questions? Contact us today.

Phone: +1 (754) 242 9682 | Email: info@proteanbiodx.com 

Screen Shot 2022-01-18 at 1.36.03 PM.png